NASDAQ:MGNX MacroGenics (MGNX) Stock Price, News & Analysis $5.55 +0.05 (+0.91%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.46▼$5.7750-Day Range$4.07▼$5.5552-Week Range$3.14▼$21.88Volume630,854 shsAverage Volume926,417 shsMarket Capitalization$347.60 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get MacroGenics alerts: Email Address MacroGenics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside116.2% Upside$12.00 Price TargetShort InterestHealthy13.24% of Float Sold ShortDividend StrengthN/ASustainability-1.61Upright™ Environmental ScoreNews Sentiment0.20Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.04) to ($2.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.58 out of 5 starsMedical Sector92nd out of 936 stocksPharmaceutical Preparations Industry33rd out of 436 stocks 4.3 Analyst's Opinion Consensus RatingMacroGenics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 6 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageMacroGenics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about MacroGenics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted13.24% of the float of MacroGenics has been sold short.Short Interest Ratio / Days to CoverMacroGenics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MacroGenics has recently decreased by 1.78%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMacroGenics does not currently pay a dividend.Dividend GrowthMacroGenics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMacroGenics has received a 66.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Monoclonal antibodies" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for MacroGenics is -1.61. Previous Next 1.8 News and Social Media Coverage News SentimentMacroGenics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for MacroGenics this week, compared to 3 articles on an average week.Search InterestOnly 7 people have searched for MGNX on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added MacroGenics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MacroGenics insiders have not sold or bought any company stock.Percentage Held by Insiders11.30% of the stock of MacroGenics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MacroGenics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MacroGenics are expected to grow in the coming year, from ($3.04) to ($2.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MacroGenics is -14.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MacroGenics is -14.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMacroGenics has a P/B Ratio of 2.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about MacroGenics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.Click here to learn more. About MacroGenics Stock (NASDAQ:MGNX)MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Read More MGNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MGNX Stock News HeadlinesJuly 26 at 8:00 PM | globenewswire.comSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of MacroGenics, Inc. Securities and Sets a Lead Plaintiff Deadline of September 24, 2024July 24 at 1:29 PM | globenewswire.comMacroGenics (MGNX) Investigating Three of Five Patient Deaths in TAMARACK Study of Vobra Duo, Stock Flat After May 10, 2024 Crash – Hagens BermanJuly 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."July 22, 2024 | finance.yahoo.comMGNX Aug 2024 3.000 call (MGNX240816C00003000)July 21, 2024 | americanbankingnews.comMacroGenics, Inc. (NASDAQ:MGNX) Receives $12.00 Consensus PT from BrokeragesJuly 19, 2024 | globenewswire.comInvestigation Into MacroGenics (MGNX) Announced by Hagens BermanJuly 16, 2024 | globenewswire.comMacroGenics (MGNX) Investigating Three of Five Patient Deaths in TAMARACK Study of Vobra Duo, Stock Flat After May 10, 2024 Crash – Hagens BermanJuly 10, 2024 | globenewswire.comMacroGenics (MGNX) Investigating Three of Five Patient Deaths in TAMARACK Study of Vobra Duo, Stock Flat After May 10, 2024 Crash – Hagens BermanJuly 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."July 7, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNXJuly 3, 2024 | globenewswire.comMacroGenics (MGNX) Investigating Three of Five Patient Deaths in TAMARACK Study of Vobra Duo, Stock Flat After May 10, 2024 Crash – Hagens BermanJuly 2, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNXJune 30, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MacroGenics, Inc. – MGNXJune 24, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNXJune 24, 2024 | globenewswire.comMacroGenics, Inc. Investors: Company Investigated by the Portnoy Law FirmJune 22, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNXJune 20, 2024 | globenewswire.comMacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study – Hagens BermanJune 13, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNXSee More Headlines Receive MGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/27/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MGNX CUSIPN/A CIK1125345 Webwww.macrogenics.com Phone(301) 251-5172Fax301-251-5321Employees339Year Founded2000Price Target and Rating Average Stock Price Target$12.00 High Stock Price Target$25.00 Low Stock Price Target$4.00 Potential Upside/Downside+116.2%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,060,000.00 Net Margins-53.60% Pretax Margin-53.60% Return on Equity-98.01% Return on Assets-51.32% Debt Debt-to-Equity RatioN/A Current Ratio3.63 Quick Ratio3.61 Sales & Book Value Annual Sales$58.75 million Price / Sales5.92 Cash FlowN/A Price / Cash FlowN/A Book Value$2.46 per share Price / Book2.26Miscellaneous Outstanding Shares62,630,000Free Float55,555,000Market Cap$347.60 million OptionableOptionable Beta2.08 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Scott Koenig M.D. (Age 72)Ph.D., President, CEO & Director Comp: $1.2MMr. James Karrels (Age 57)Senior VP, CFO & Corporate Secretary Comp: $693.31kDr. Stephen L. Eck M.D. (Age 69)Ph.D., Senior VP of Clinical Development & Chief Medical Officer Comp: $766.85kMr. Eric Blasius Risser (Age 51)Chief Operating Officer Comp: $651.36kDr. Thomas M. Spitznagel Ph.D. (Age 57)Senior Vice President of Technical Operations Comp: $550.97kDr. Ezio Bonvini M.D. (Age 70)Senior VP of Research & Chief Scientific Officer Comp: $612.21kMr. Jeffrey Stuart Peters (Age 53)Senior VP, General Counsel & Corporate Compliance Officer Ms. Lynn Cilinski (Age 66)VP, Controller & Treasurer More ExecutivesKey CompetitorsEpizymeNASDAQ:EPZMPuma BiotechnologyNASDAQ:PBYIRepare TherapeuticsNASDAQ:RPTXIntercept PharmaceuticalsNASDAQ:ICPTArcus BiosciencesNYSE:RCUSView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 12,237 shares on 7/26/2024Ownership: 0.418%Diversified Trust CoBought 4,467 shares on 7/16/2024Ownership: 0.029%RA Capital Management L.P.Sold 1,971,056 shares on 5/17/2024Ownership: 3.324%Jacobs Levy Equity Management Inc.Bought 33,039 shares on 5/16/2024Ownership: 0.236%Janus Henderson Group PLCBought 33,403 shares on 5/16/2024Ownership: 0.053%View All Insider TransactionsView All Institutional Transactions MGNX Stock Analysis - Frequently Asked Questions How have MGNX shares performed this year? MacroGenics' stock was trading at $9.62 at the beginning of 2024. Since then, MGNX shares have decreased by 42.3% and is now trading at $5.55. View the best growth stocks for 2024 here. How were MacroGenics' earnings last quarter? MacroGenics, Inc. (NASDAQ:MGNX) announced its earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.84) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.17. The biopharmaceutical company had revenue of $9.10 million for the quarter, compared to analysts' expectations of $13.63 million. MacroGenics had a negative trailing twelve-month return on equity of 98.01% and a negative net margin of 53.60%. What is Scott Koenig's approval rating as MacroGenics' CEO? 12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees. Who are MacroGenics' major shareholders? Top institutional investors of MacroGenics include Bank of New York Mellon Corp (0.42%) and Diversified Trust Co (0.03%). Insiders that own company stock include Target N V Biotech, James Karrels, Ezio Bonvini, Edward Hurwitz and Jeffrey Stuart Peters. View institutional ownership trends. How do I buy shares of MacroGenics? Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of MacroGenics own? Based on aggregate information from My MarketBeat watchlists, some other companies that MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE). This page (NASDAQ:MGNX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.